Factors associated with survival among patients with AIDS-related primary central nervous system lymphoma

AIDS

Volumn 28, Issue 3, 2014, Pages 397-405

  Uldrick, Thomas S ^a   Pipkin, Sharon ^b   Scheer, Susan ^b   Hessol, Nancy A ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

AIDS; AIDS related lymphoma; Brain neoplasms; HAART; Prognosis; Risk factors; Time factors

Indexed keywords

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CALIFORNIA; CENTRAL NERVOUS SYSTEM NEOPLASMS; FEMALE; HUMANS; LYMPHOMA, AIDS-RELATED; MALE; MIDDLE AGED; SAN FRANCISCO; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84894079665     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000030     Document Type: Article

References (58)

1. Ziegler JL, Beckstead JA, Volberding PA, Abrams DI, Levine AM, Lukes RJ, et al. Non-Hodgkin's lymphoma in 90 homosexual men. Relation to generalized lymphadenopathy and the acquired immunodeficiency syndrome. N Engl J Med 1984; 311:565-570.
2. Shiels MS, Pfeiffer RM, Hall HI, Li J, Goedert JJ, Morton LM, et al. Proportions of Kaposi sarcoma, selected non-Hodgkin lymphomas, and cervical cancer in the United States occurring in persons with AIDS, 1980-2007. JAMA 2011; 305:1450- 1459.
3. Centers for Disease Control and Prevention. Current Trends Revision of the case definition of acquired immunodeficiency syndrome for national reporting - United States. MMWR Morbid Mortal Wkly Rep 1985; 34:373-375.
4. Baumgartner JE, Rachlin JR, Beckstead JH, Meeker TC, Levy RM, Wara WM, et al. Primary central nervous system lymphomas: natural history and response to radiation therapy in 55 patients with acquired immunodeficiency syndrome. J Neurosurg 1990; 73:206-211.
5. Ling SM, Roach M 3rd, Larson DA, Wara WM. Radiotherapy of primary central nervous system lymphoma in patients with and without human immunodeficiency virus. Ten years of treatment experience at the University of California San Francisco. Cancer 1994; 73:2570-2582.
6. Bower M, Powles T, Nelson M, Mandalia S, Gazzard B, Stebbing J. Highly active antiretroviral therapy and human immunodeficiency virus-associated primary cerebral lymphoma. J Natl Cancer Inst 2006; 98:1088-1091.
7. Pierce MA, Johnson MD, Maciunas RJ, Murray MJ, Allen GS, Harbison MA, et al. Evaluating contrast-enhancing brain lesions in patients with AIDS by using positron emission tomography. Ann Intern Med 1995; 123:594-598.
8. Evaluation and management of intracranial mass lesions in AIDS. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 1998; 50:21- 26.
9. Hoffman JM, Waskin HA, Schifter T, Hanson MW, Gray L, Rosenfeld S, et al. FDG-PET in differentiating lymphoma from nonmalignant central nervous system lesions in patients with AIDS. J Nucl Med 1993; 34:567-575.
10. Antinori A, De Rossi G, Ammassari A, Cingolani A, Murri R, Di Giuda D, et al. Value of combined approach with thallium-201 single-photon emission computed tomography and Epstein- Barr virus DNA polymerase chain reaction in CSF for the diagnosis of AIDS-related primary CNS lymphoma. J Clin Oncol 1999; 17:554-560.
11. MacMahon EM, Glass JD, Hayward SD, Mann RB, Becker PS, Charache P, et al. Epstein-Barr virus in AIDS-related primary central nervous system lymphoma. Lancet 1991; 338:969- 973.
12. Cingolani A, De Luca A, Larocca LM, Ammassari A, Scerrati M, Antinori A, et al. Minimally invasive diagnosis of acquired immunodeficiency syndrome- related primary central nervous system lymphoma. J Natl Cancer Inst 1998; 90:364-369.
13. Yarchoan R, Jaffe ES, Little R. Diagnosing central nervous system lymphoma in the setting of AIDS: a step forward. J Natl Cancer Inst 1998; 90:346-347.
14. Skiest DJ, Crosby C. Survival is prolonged by highly active antiretroviral therapy in AIDS patients with primary central nervous system lymphoma. AIDS 2003; 17:1787-1793.
15. Biggar RJ, Engels EA, Ly S, Kahn A, Schymura MJ, Sackoff J, et al. Survival after cancer diagnosis in persons with AIDS. J Acquir Immune Defic Syndr 2005; 39:293-299.
16. Hoffmann C, Tabrizian S, Wolf E, Eggers C, Stoehr A, Plettenberg A, et al. Survival of AIDS patients with primary central nervous system lymphoma is dramatically improved by HAART-induced immune recovery. AIDS 2001; 15:2119- 2127.
17. Newell ME, Hoy JF, Cooper SG, DeGraaff B, Grulich AE, Bryant M, et al. Human immunodeficiency virus-related primary central nervous system lymphoma: factors influencing survival in 111 patients. Cancer 2004; 100:2627-2636.
18. Diamond C, Taylor TH, Im T, Miradi M, Wallace M, Anton- Culver H. Highly active antiretroviral therapy is associated with improved survival among patients with AIDS-related primary central nervous system non-Hodgkin's lymphoma. Curr HIV Res 2006; 4:375-378.
19. Aboulafia DM, Puswella AL. Highly active antiretroviral therapy as the sole treatment for AIDS-related primary central nervous system lymphoma: a case report with implications for treatment. AIDS Patient Care STDS 2007; 21:900- 907.
20. Travi G, Ferreri AJ, Cinque P, Gerevini S, Ponzoni M, Terreni MR, et al. Long-term remission of HIV-associated primary CNS lymphoma achieved with highly active antiretroviral therapy alone. J Clin Oncol 2012; 30:e119-e121.
21. Gasser O, Bihl FK, Wolbers M, Loggi E, Steffen I, Hirsch HH, et al. HIV patients developing primary CNS lymphoma lack EBV-specific CD4R T cell function irrespective of absolute CD4R T cell counts. PLoS Med 2007; 4:e96.
22. Pipkin S, Scheer S, Okeigwe I, Schwarcz S, Harris DH, Hessol NA. The effect of HAART and calendar period on Kaposís sarcoma and non-Hodgkin lymphoma: results of a match between an AIDS and cancer registry. AIDS 2011; 25:463- 471.
23. Skiest DJ, Erdman W, Chang WE, Oz OK, Ware A, Fleckenstein J. SPECT thallium-201 combined with Toxoplasma serology for the presumptive diagnosis of focal central nervous system mass lesions in patients with AIDS. J Infect 2000; 40:274-281.
24. Norden AD, Drappatz J, Wen PY, Claus EB. Survival among patients with primary central nervous system lymphoma, 1973-2004. J Neurooncol 2011; 101:487-493.
25. Haldorsen IS, Espeland A, Larsen JL, Mella O. Diagnostic delay in primary central nervous system lymphoma. Acta Oncol 2005; 44:728-734.
26. Achenbach CJ, Cole SR, Kitahata MM, Casper C, Willig JH, Mugavero MJ, et al. Mortality after cancer diagnosis in HIVinfected individuals treated with antiretroviral therapy. AIDS 2011; 25:691-700.
27. Kreisl TN, Panageas KS, Elkin EB, Deangelis LM, Abrey LE. Treatment patterns and prognosis in patients with human immunodeficiency virus and primary central system lymphoma. Leuk Lymphoma 2008; 49:1710-1716.
28. Schwarcz SK, Hsu LC, Parisi MK, Katz MH. The impact of the 1993 AIDS case definition on the completeness and timeliness of AIDS surveillance. AIDS 1999; 13:1109-1114.
29. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41 (RR-17):1-19.
30. Frisch M, Biggar RJ, Engels EA, Goedert JJ. Association of cancer with AIDS-related immunosuppression in adults. JAMA 2001; 285:1736-1745.
31. Gallagher B, Wang Z, Schymura MJ, Kahn A, Fordyce EJ. Cancer incidence in New York State acquired immunodeficiency syndrome patients. Am J Epidemiol 2001; 154:544-556.
32. Goedert JJ, Cote TR, Virgo P, Scoppa SM, Kingma DW, Gail MH, et al. Spectrum of AIDS-associated malignant disorders. Lancet 1998; 351:1833-1839.
33. Grulich AE, Li Y, McDonald A, Correll PK, Law MG, Kaldor JM. Rates of non-AIDS-defining cancers in people with HIV infection before and after AIDS diagnosis. AIDS 2002; 16:1155- 1161.
34. Hessol NA, Pipkin S, Schwarcz S, Cress RD, Bacchetti P, Scheer S. The impact of highly active antiretroviral therapy on non- AIDS-defining cancers among adults with AIDS. Am J Epidemiol 2007; 165:1143-1153.
35. IARC. WHO classification of tumours of haematopoetic and lymphoid tissues. 4th ed. Lyon: IARC; 2008.
36. Biggar RJ, Chaturvedi AK, Goedert JJ, Engels EA. AIDS-related cancer and severity of immunosuppression in persons with AIDS. J Natl Cancer Inst 2007; 99:962-972.
37. Engels EA, Pfeiffer RM, Goedert JJ, Virgo P, McNeel TS, Scoppa SM, et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 2006; 20:1645- 1654.
38. Forsyth PA, Yahalom J, DeAngelis LM. Combined-modality therapy in the treatment of primary central nervous system lymphoma in AIDS. Neurology 1994; 44:1473-1479.
39. Jacomet C, Girard PM, Lebrette MG, Farese VL, Monfort L, Rozenbaum W. Intravenous methotrexate for primary central nervous system non-Hodgkin's lymphoma in AIDS. AIDS 1997; 11:1725-1730.
40. Nagai H, Odawara T, Ajisawa A, Tanuma J, Hagiwara S, Watanabe T, et al. Whole brain radiation alone produces favourable outcomes for AIDS-related primary central nervous system lymphoma in the HAART era. Eur J Haematol 2010; 84:499-505.
41. Bromberg JE, Breems DA, Kraan J, Bikker G, van der Holt B, Smitt PS, et al. CSF flow cytometry greatly improves diagnostic accuracy in CNS hematologic malignancies. Neurology 2007; 68:1674-1679.
42. Kraan J, Gratama JW, Haioun C, Orfao A, Plonquet A, Porwit A, et al. Flow cytometric immunophenotyping of cerebrospinal fluid. Curr Protoc Cytom 2008Chapter 6:Unit 6 25.
43. Schroers R, Baraniskin A, Heute C, Vorgerd M, Brunn A, Kuhnhenn J, et al. Diagnosis of leptomeningeal disease in diffuse large B-cell lymphomas of the central nervous system by flow cytometry and cytopathology. Eur J Haematol 2010; 85:520-528.
44. Abrey LE, Batchelor TT, Ferreri AJ, Gospodarowicz M, Pulczynski EJ, Zucca E, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 2005; 23:5034-5043.
45. Raez LE, Patel P, Feun L, Restrepo A, Raub WA Jr, Cassileth PA. Natural history and prognostic factors for survival in patients with acquired immune deficiency syndrome (AIDS)-related primary central nervous system lymphoma (PCNSL). Crit Rev Oncog 1998; 9:199-208.
46. Antinori A, Larussa D, Cingolani A, Lorenzini P, Bossolasco S, Finazzi MG, et al. Prevalence, associated factors, and prognostic determinants of AIDS- related toxoplasmic encephalitis in the era of advanced highly active antiretroviral therapy. Clin Infect Dis 2004; 39:1681-1691.
47. Bicanic T, Muzoora C, Brouwer AE, Meintjes G, Longley N, Taseera K, et al. Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients. Clin Infect Dis 2009; 49:702-709.
48. Centers for Disease Control and Prevention. Disparities in diagnoses of HIV infection between blacks/African Americans and other racial/ethnic populations - 37 states, 2005-2008. MMWR Morb Mortal Wkly Rep 2011; 60:93-98.
49. Pulido JS, Vierkant RA, Olson JE, Abrey L, Schiff D, O'Neill BP. Racial differences in primary central nervous system lymphoma incidence and survival rates. Neuro-Oncology 2009; 11:318- 322.
50. Arnold M, Hsu L, Pipkin S, McFarland W, Rutherford GW. Race, place and AIDS: the role of socioeconomic context on racial disparities in treatment and survival in San Francisco. Soc Sci Med 2009; 69:121-128.
51. Silverberg MJ, Leyden W, Quesenberry CP Jr, Horberg MA. Race/ethnicity and risk of AIDS and death among HIV-infected patients with access to care. J Gen Intern Med 2009; 24:1065- 1072.
52. Millett GA, Peterson JL, Flores SA, Hart TA, Jeffries WLT, Wilson PA, et al. Comparisons of disparities and risks of HIV infection in black and other men who have sex with men in Canada, UK, and USA: a meta-analysis. Lancet 2012; 380:341-348.
53. Hanna DB, Selik RM, Tang T, Gange SJ. Disparities among US states in HIV-related mortality in persons with HIV infection, 2001-2007. AIDS 2012; 26:95-103.
54. King WD, Minor P, Ramirez Kitchen C, Ore LE, Shoptaw S, Victorianne GD, et al. Racial, gender and geographic disparities of antiretroviral treatment among US Medicaid enrolees in 1998. J Epidemiol Community Health 2008; 62:798-803.
55. Suneja G, Shiels MS, Melville SK, Williams MA, Rengan R, Engels EA. Disparities in the treatment and outcomes of lung cancer among HIV- infected people in Texas. AIDS 2013; 27:459-468.
56. Grann VR, Ziv E, Joseph CK, Neugut AI, Wei Y, Jacobson JS, et al. Duffy (Fy), DARC, and neutropenia among women from the United States, Europe and the Caribbean. Br J Haematol 2008; 143:288-293.
57. Abrey LE, Panageas KS. Identifying and addressing barriers to the delivery of optimal therapy for primary central nervous system lymphoma in the broader community. Leuk Lymphoma 2006; 47:2449-2452.
58. Persad GC, Little RF, Grady C. Including persons with HIV infection in cancer clinical trials. J Clin Oncol 2008; 26:1027- 1032.